EUVIMEDEUVIMED entdecken
Open Access

Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?

A Boast iD, W Zhang, H Soeorg, G Gonis, A Di Carlo, A Daley, N Curtis, B McWhinney, J P J Ungerer, A Lei, J F Standing, A Gwee iD

Antimicrobial Agents and Chemotherapy · 2024

DOI: 10.1128/aac.00747-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von A Boast und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Medicine and Laboratory Services, The Royal Children's Hospital Melbourne, Parkville, Australia. Hauptthemen laut MEDLINE: Ceftriaxone, Anti-Bacterial Agents, Meningitis, Bacterial, Microbial Sensitivity Tests. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Guidelines for bacterial meningitis in children recommend intravenous ceftriaxone 50 mg/kg (max 2 g) twice daily (BD) or 100 mg/kg (max 4 g) once daily (OD), leaving the decision regarding the dose frequency to the prescriber. We investigated the cerebrospinal fluid (CSF) penetration of ceftriaxone to evaluate whether one dosing regimen is superior. Unbound ceftriaxone concentrations were measured in serum and CSF samples from children aged 0–18 years treated with ceftriaxone if there was a sample remaining after clinical tests were performed. A serum–CSF population pharmacokinetic model was developed using non-linear mixed-effects modeling. The once- and twice-daily dosing regimens were simulated, and the probability of target attainment (PTA) was determined for maintaining a CSF concentration above a minimum inhibitory concentration (MIC) of 1 mg/L for common meningitis pathogens and 4 mg/L for Staphylococcus aureus for 100% of the dosing interval. Sixteen serum and 87 CSF samples were collected from 98 children (age range 0.1–18.5 years). The final two-compartment serum–CSF model included a renal maturation function with weight scaling on clearance and volume of distribution. The estimated serum:CSF uptake was 20.1%. For MIC 1 mg/L, the 24 h PTA was higher for OD (88%) compared with BD (53%) dosing, although both achieved a 100% PTA at steady state. For S. aureus (MIC 4 mg/L), neither dosing regimen was sufficient. Our findings support the use of a 100 mg/kg once daily regimen for empirical treatment of bacterial meningitis due to earlier achievement of the pharmacodynamic target. Neither dosing regimen was adequate for S. aureus meningitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftriaxoneAnti-Bacterial AgentsMeningitis, BacterialMicrobial Sensitivity TestsHumansChildChild, PreschoolInfantAdolescentFemaleMaleDrug Administration ScheduleInfant, NewbornStaphylococcus aureus

Stichwörter der Autor:innen

cephalosporinscerebrospinal fluid penetrationdosingmeningitispediatricspopulation pharmacokinetics

Substanzen

CeftriaxoneAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of General Medicine and Laboratory Services, The Royal Children's Hospital Melbourne, Parkville, Australia.
  • Antimicrobials and Infectious Diseases Group, Murdoch Children's Research Institute, Melbourne, Australia.
  • Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
  • Infection, Immunity and Inflammation, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.
  • Department of Chemical Pathology, Pathology Queensland, Brisbane, Australia.
  • Faculty of Health and Behavioural Sciences, University of Queensland, Brisbane, Australia.

ORCID-Profile: A Boast, A Gwee

Zitieren

APA

Boast, A., Zhang, W., Soeorg, H., Gonis, G., Di Carlo, A., Daley, A., Curtis, N., McWhinney, B., Ungerer, J. P. J., Lei, A., Standing, J. F., & Gwee, A. (2024). Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00747-24

Vancouver

Boast A, Zhang W, Soeorg H, Gonis G, Di Carlo A, Daley A, et al. Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00747-24

BibTeX
@article{Boast2024,
  author = {Boast, A and Zhang, W and Soeorg, H and Gonis, G and Di Carlo, A and Daley, A and Curtis, N and McWhinney, B and Ungerer, J P J and Lei, A and Standing, J F and Gwee, A},
  title = {Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  doi = {10.1128/aac.00747-24}
}
Kostenlos starten →